Recent developments include Viking Therapeutics reporting wider Q3 losses alongside advancement of VK2735 Phase 3 clinical programs, initiation of pivotal Phase 3 trials for the oral formulation of VK2735, and ongoing corporate updates reflecting clinical progress and financial results.

• Viking Therapeutics reported wider Q3 losses as VK2735 Phase 3 programs advanced, reflecting increased clinical development expenses [N1].
• The company held its Q3 2026 earnings call discussing financial results and progress in clinical trials, including updates on VK2735 and other pipeline candidates [N2].
• Viking Therapeutics released its third quarter 2026 financial results and provided a corporate update highlighting ongoing Phase 3 trials and research activities [N3].
• Initiation of the SUNRISE Phase 3 clinical program for the oral formulation of VK2735 was announced, marking a key milestone in the company’s obesity drug development efforts [N1].
• The company continues to manage operating losses while advancing clinical-stage programs, with no revenue generation reported [N1].

Viking Therapeutics has advanced multiple drug candidates into late-stage clinical trials, including VK2735 in Phase 3 for obesity and VK2809 in Phase 2b for metabolic disorders, demonstrating progress in its pipeline. Positive Phase 2 and Phase 1b data support the potential of these candidates. The company’s strong liquidity position provides financial resources to continue development activities. If the legal dispute with Ligand Pharmaceuticals is resolved favorably, Viking retains exclusive rights to key programs, supporting its long-term growth prospects. The company’s focus on high unmet medical needs in metabolic and endocrine diseases positions it to address significant market opportunities.

The company faces substantial risks including the uncertainty of clinical trial outcomes and regulatory approvals, which could delay or prevent commercialization of its drug candidates. The ongoing legal dispute with Ligand Pharmaceuticals over licensing rights to the TR-Beta Program creates uncertainty and potential loss of critical intellectual property. Viking has not generated revenue and continues to incur significant operating losses, relying on capital markets for funding, which may lead to dilution or operational constraints. Competition from established pharmaceutical companies and alternative therapies may limit commercial opportunities. Failure to establish strategic collaborations could hinder development and commercialization efforts.

Viking Therapeutics’ moat is primarily based on its proprietary drug candidates and exclusive licensing agreements with Ligand Pharmaceuticals, which provide rights to key compounds and intellectual property. The company’s focus on metabolic and endocrine disorders with unmet medical needs, combined with its advancing clinical-stage pipeline, contributes to its competitive positioning. However, the moat is challenged by the ongoing legal dispute over licensing rights, the inherent risks of clinical development, and competition from established pharmaceutical companies with approved therapies. The company’s ability to maintain exclusive rights and successfully navigate regulatory pathways will be critical to sustaining its competitive advantage.

• Clinical Development Risks: The success of Viking Therapeutics depends on the outcomes of clinical trials for its drug candidates, which are subject to delays, negative or inconclusive results, and regulatory challenges that could impede approval and commercialization.
• Licensing and Legal Risks: The company is involved in a legal dispute with Ligand Pharmaceuticals regarding termination of the license for the TR-Beta Program, which includes key drug candidates VK2809 and VK0214. An adverse outcome could result in loss of intellectual property rights and harm to the business.
• Financial Risks: Viking Therapeutics has not generated revenue and incurs significant operating losses. It depends on raising additional capital to fund operations, which may not be available on favorable terms and could dilute existing shareholders or restrict business activities.
• Competitive Risks: The company faces competition from established pharmaceutical companies with approved therapies and ongoing development programs, which may reduce the commercial potential of Viking’s drug candidates.
• Operational Risks: Dependence on third-party contract research organizations, clinical trial sites, and manufacturers introduces risks related to compliance, quality, and timely execution of clinical development activities.

• Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drug candidates for metabolic and endocrine disorders including obesity, nonalcoholic steatohepatitis (NASH), and X-linked adrenoleukodystrophy (X-ALD).
• The company has not generated any revenue to date and does not expect revenue until regulatory approval and commercialization of its drug candidates or entering collaborative agreements.
• Key drug candidates include VK2735 (subcutaneous and oral formulations) in Phase 3 clinical trials, VK2809 in Phase 2b, VK0214 completed Phase 1b, VK5211 and VK0612 in Phase 2, VK3019 in Phase 1 SAD trial, and preclinical programs DGAT-1 and EPOR.
• The company incurred significant research and development expenses: $344.955 million in 2025 compared to $101.644 million in 2024, primarily due to clinical studies, manufacturing, stock-based compensation, and salaries.
• General and administrative expenses were $48.387 million in 2025, slightly decreased from $49.277 million in 2024, with changes driven by legal, patent services, stock-based compensation, insurance, and salaries.
• As of September 30, 2026, Viking Therapeutics had cash and cash equivalents of $677.6 million, current assets of $973.0 million, current liabilities of $133.9 million, resulting in a current ratio of 7.27 and a cash ratio of 6.59, indicating strong liquidity.
• The company reported a net loss of $183.186 million for the nine months ended September 30, 2026, with basic and diluted EPS of -$1.55 per share.
• Viking Therapeutics is substantially dependent on licensed technologies from Ligand Pharmaceuticals under a Master License Agreement, which grants exclusive worldwide rights to several drug candidates including VK2809 and VK0214.
• There is an ongoing legal dispute with Ligand Pharmaceuticals regarding the termination of the license for the TR-Beta Program, which includes VK2809 and VK0214; Viking has filed a cross-complaint asserting the termination is invalid and retains exclusive rights.
• The company faces typical clinical-stage risks including uncertainty of regulatory approval, clinical trial outcomes, patient enrollment, costs, and potential side effects.
• VK2735 subcutaneous and oral formulations have reported positive Phase 2 results and have initiated Phase 3 programs (VANQUISH and SUNRISE respectively).
• VK2809 showed positive Phase 2b results and 52-week histologic data from the VOYAGE study.
• VK0214 completed a Phase 1b clinical trial with positive data in patients with X-ALD.
• The company has not yet established strategic collaborations for clinical development of its drug candidates and may seek partnerships in the future.
• Recent news highlights include wider Q3 losses as VK2735 Phase 3 programs advance, and initiation of pivotal Phase 3 trials for VK2735 oral formulation.
• The company continues to incur significant operating losses and has an accumulated deficit of $1.317 billion as of September 30, 2026.
• Research and development expenses are dynamically managed based on scientific data, regulatory progress, market potential, and resource availability.
• The company expenses all research and development costs as incurred, including payments to CROs, clinical trial sites, and manufacturers.
• General and administrative expenses include costs related to being a public company, legal fees, insurance, and stock-based compensation.
• The company recognizes stock-based compensation using the Black-Scholes model and straight-line allocation over vesting periods.
• Liquidity ratios derived from SEC filings indicate strong short-term financial health as of September 30, 2026.
• Recent quarterly filings emphasize risks including dependency on licensed technology, clinical trial uncertainties, potential delays, and capital requirements.
• The company may need to raise additional capital to fund operations, which could cause dilution or operational restrictions.
• The company has publicly disclosed detailed financial results and corporate updates in its Q3 2026 earnings release and earnings call transcript.